OLMA Olema Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: OLMA
Price (delayed)
$7.95
Market cap
$545.64M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.87
Enterprise value
$497.92M
Relative Growth:
Rel. Growth:
7
Relative Strength:
Rel. Strength:
77
Relative Valuation:
Rel. Valuation:
N/A
Relative Profitability:
Rel. Profitability:
5
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Its lead product candidate, OP-1250, is
Highlights
OLMA's EPS is up by 9% YoY
Olema Pharmaceuticals's equity has soared by 52% YoY but it has decreased by 10% from the previous quarter
OLMA's quick ratio is down by 28% since the previous quarter but it is up by 21% year-on-year
The debt has surged by 142% year-on-year
Olema Pharmaceuticals's net income has decreased by 30% YoY and by 10% from the previous quarter
Key stats
What are the main financial stats of OLMA
Market
Valuations
Earnings
Shares outstanding
68.63M
Market cap
$545.64M
Enterprise value
$497.92M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.58
Price to sales (P/S)
N/A
PEG
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$157.13M
Net income
-$142.3M
EBIT
-$142.3M
EBITDA
-$140.67M
Free cash flow
-$127.16M
Per share
Balance sheet
Liquidity
EPS
-$1.87
EPS diluted
-$1.87
Free cash flow per share
-$1.49
Book value per share
$5.05
Revenue per share
$0
TBVPS
$4.47
Total assets
$382M
Total liabilities
$36.77M
Debt
$4.76M
Equity
$345.24M
Working capital
$334.56M
Debt to equity
0.01
Current ratio
11.09
Quick ratio
10.91
Net debt/EBITDA
0.34
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-38.6%
Return on equity
-42.6%
Return on invested capital
-53.1%
Return on capital employed
-40.8%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
OLMA stock price
How has the Olema Pharmaceuticals stock price performed over time
Intraday
-3.05%
1 week
-7.99%
1 month
-28.38%
1 year
-34.08%
YTD
36.36%
QTD
-18.79%
Financial performance
How have Olema Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$157.13M
Net income
-$142.3M
Gross margin
N/A
Net margin
N/A
Olema Pharmaceuticals's net income has decreased by 30% YoY and by 10% from the previous quarter
The operating income has decreased by 29% YoY and by 10% QoQ
Price vs fundamentals
How does OLMA's price correlate with its fundamentals
Growth
What is Olema Pharmaceuticals's growth rate over time
Valuation
What is Olema Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.58
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
OLMA's EPS is up by 9% YoY
Olema Pharmaceuticals's equity has soared by 52% YoY but it has decreased by 10% from the previous quarter
OLMA's price to book (P/B) is 25% less than its 5-year quarterly average of 2.1 but 13% more than its last 4 quarters average of 1.4
Efficiency
How efficient is Olema Pharmaceuticals business performance
The return on invested capital has grown by 7% year-on-year
Olema Pharmaceuticals's ROE has increased by 3.6% YoY
The return on assets has grown by 4.2% year-on-year
Dividends
What is OLMA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for OLMA.
Financial health
How did Olema Pharmaceuticals financials performed over time
Olema Pharmaceuticals's total assets has soared by 50% YoY but it has decreased by 7% from the previous quarter
Olema Pharmaceuticals's total liabilities has increased by 40% from the previous quarter and by 34% YoY
The debt is 99% smaller than the equity
The debt has surged by 142% year-on-year
Olema Pharmaceuticals's equity has soared by 52% YoY but it has decreased by 10% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.